ReviewRegulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders

- ABC efflux transporters are important element of BBB.
- ABC efflux transporters provide neuroprotection against several neurotoxins.
- ABC efflux transporters contribute to the pharmacoresistance against CNS drugs.
- Several stressors modulate the activity of ABC efflux transporters at BBB.
- Pathological alterations of ABC efflux transporters are associated with many CNS disorders.

The strength of the blood-brain barrier (BBB) in providing protection to the central nervous system from exposure to circulating chemicals is maintained by tight junctions between endothelial cells and by a broad range of transporter proteins that regulate exchange between CNS and blood. The most important transporters that restrict the permeability of large number of toxins as well as therapeutic agents are the ABC transporters. Among them, P-gp, BCRP, MRP1 and MRP2 are the utmost studied. These efflux transporters are neuroprotective, limiting the brain entry of neurotoxins; however, they could also restrict the entry of many therapeutics and contribute to CNS pharmacoresistance. Characterization of several regulatory pathways that govern expression and activity of ABC efflux transporters in the endothelium of brain capillaries have led to an emerging consensus that these processes are complex and contain several cellular and molecular elements. Alterations in ABC efflux transporters expression and/or activity occur in several neurological diseases. Here, we review the signaling pathways that regulate expression and transport activity of P-gp, BCRP, MRP1 and MRP2 as well as how their expression/activity changes in neurological diseases.This article is part of a Special Issue entitled SI: Neuroprotection.